Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 27.
Article
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
|
Asher, Samir;
Kazantzi, Aikaterini;
Dekaj, Fatjon;
Steventon, Luke;
Khatun, Aisha;
Ainley, Louise;
McMillan, Annabel;
... Popat, Rakesh; + view all
(2022)
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma.
Haematologica
, 107
(12)
pp. 2961-2965.
10.3324/haematol.2022.281322.
|
|
Camilleri, M;
Sive, J;
Wilson, W;
Pang, G;
Jenner, R;
Phillips, E;
Popat, R;
... Yong, K; + view all
(2021)
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British Journal of Haematology
, 192
(1)
E14-E16.
10.1111/bjh.17168.
|
|
Camilleri, M;
Cuadrado, M;
Phillips, E;
Wilson, W;
Jenner, R;
Pang, G;
Kamora, S;
... Yong, K; + view all
(2021)
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British Journal of Haematology
10.1111/bjh.17377.
(In press).
|
 |
|
Chapman, MA;
Sive, J;
Ambrose, J;
Roddie, C;
Counsell, N;
Lach, A;
Abbasian, M;
... Yong, K; + view all
(2018)
RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
, 132
(20)
pp. 2154-2165.
10.1182/blood-2018-05-849893.
|
|
Chavda, SJ;
Maciocia, PM;
Mesiri, P;
Counsell, N;
Kothari, J;
Bird, A;
Mariner, C;
... Yong, K; + view all
(2019)
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
British Journal of Haematology
, 185
(2)
pp. 350-353.
10.1111/bjh.15487.
|
|
Chavda, SJ;
Pocock, R;
Cheesman, S;
Lee, K-M;
Dowling, E;
Marks, DJB;
Kyriakou, C;
... Popat, R; + view all
(2020)
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
British Journal of Haematology
10.1111/bjh.16889.
(In press).
|
|
|
Chin, M;
Sive, JI;
Allen, C;
Roddie, C;
Chavda, SJ;
Smith, D;
Blombery, P;
... Yong, KL; + view all
(2017)
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Blood Cancer Journal
, 7
, Article e610. 10.1038/bcj.2017.76.
|
|
|
Cohen, OC;
Brodermann, MH;
Blakeney, IJ;
Mahmood, S;
Sachchithanantham, S;
Ravichandran, S;
Law, S;
... Wechalekar, AD; + view all
(2020)
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Amyloid
, 27
(3)
pp. 200-205.
10.1080/13506129.2020.1765768.
|
|
Cohen, OC;
Counsell, N;
Rabin, N;
Popat, R;
Owen, RG;
Popova, B;
Schofield, O;
... Yong, KL; + view all
(2019)
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
(5)
pp. 948-951.
10.1111/bjh.15649.
|
|
Cohen, OC;
Sharpley, F;
Gillmore, JD;
Lachmann, HJ;
Sachchithanantham, S;
Mahmood, S;
Fontana, M;
... Wechalekar, AD; + view all
(2020)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis.
British Journal of Haematology
, 189
(4)
pp. 643-649.
10.1111/bjh.16401.
|
|
El-Sharkawi, D;
Ng, C-H;
Payne, EMC;
Yong, KL;
Ardeshna, KM;
Khwaja, A;
Townsend, W;
(2019)
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
British Journal of Haematology
, 185
(2)
pp. 344-347.
10.1111/bjh.15457.
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Latifoltojar, A;
Hall-Craggs, M;
Bainbridge, A;
Rabin, N;
Popat, R;
Rismani, A;
D'Sa, S;
... Punwani, S; + view all
(2017)
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
European Radiology
10.1007/s00330-017-4907-8.
(In press).
|
|
|
Latifoltojar, A;
Hall-Craggs, M;
Rabin, N;
Popat, R;
Bainbridge, A;
Dikaios, N;
Sokolska, M;
... Yong, K; + view all
(2017)
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.
British Journal of Haematology
, 176
(2)
pp. 222-233.
10.1111/bjh.14401.
|
|
Maciocia, N;
Melville, A;
Cheesman, S;
Sharpley, F;
Ramasamy, K;
Streetly, M;
Jenner, M;
... Rabin, N; + view all
(2017)
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
British Journal of Haematology
, 176
(6)
pp. 908-917.
10.1111/bjh.14547.
|
|
|
Manwani, R;
Hegenbart, U;
Mahmood, S;
Sachchithanantham, S;
Kyriakou, C;
Yong, K;
Popat, R;
... Wechalekar, A; + view all
(2018)
Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Blood Cancer Journal
, 8
, Article 101. 10.1038/s41408-018-0137-9.
|
|
|
Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Gillmore, JD;
Yong, K;
Rabin, N;
... Wechalekar, AD; + view all
(2019)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
British Journal of Haematology
, 187
(5)
pp. 638-641.
10.1111/bjh.16122.
|
|
Popat, R;
Counsell, N;
De Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, JD;
Adedayo, T;
... Yong, K; + view all
(2021)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
British Journal of Haematology
, 193
(3)
e19-e22.
10.1111/bjh.17391.
|
|
Popat, R;
Brown, SR;
Flanagan, L;
Hall, A;
Gregory, W;
Kishore, B;
Streetly, M;
... Cavenagh, J; + view all
(2019)
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
British Journal of Haematology
, 185
(3)
pp. 573-578.
10.1111/bjh.15551.
|
|
Popat, R;
Brown, SR;
Flanagan, L;
Hall, A;
Gregory, W;
Kishore, B;
Streetly, M;
... Myeloma UK Early Phase Clinical Trial Network, .; + view all
(2016)
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
The Lancet Haematology
, 3
(12)
e572-e580.
10.1016/S2352-3026(16)30165-X.
|
|
|
Popat, R;
Warcel, D;
O'Nions, J;
Cowley, A;
Smith, S;
Tucker, WR;
Yong, K;
(2020)
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.
Haematologica
, 105
(5)
E261-E263.
10.3324/haematol.2019.235937.
|
|
|
Ravichandran, Sriram;
Mahmood, Shameem;
Wisniowski, Brenden;
Sachchithanantham, Sajitha;
Popat, Rakesh;
Lachmann, Helen;
Rabin, Neil;
... D Wechalekar, Ashutosh; + view all
(2022)
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
British Journal of Haematology
, 198
(2)
pp. 328-332.
10.1111/bjh.18216.
|
|
San-Miguel, J;
Dhakal, B;
Yong, K;
Spencer, A;
Anguille, S;
Mateos, M-V;
Fernandez de Larrea, C;
... Einsele, H; + view all
(2023)
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
New England Journal of Medicine
, 389
(4)
pp. 335-347.
10.1056/NEJMoa2303379.
|
|
|
Trudel, S;
Lendvai, N;
Popat, R;
Voorhees, PM;
Reeves, B;
Libby, EN;
Richardson, PG;
... Cohen, AD; + view all
(2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
The Lancet Oncology
, 19
(12)
pp. 1641-1653.
10.1016/S1470-2045(18)30576-X.
|
|
Xu, Ke;
Agbuduwe, Charles;
Kanellias, Nickolaos;
Wilson, William;
McMillan, Annabel;
Papanikolaou, Xenofon;
Lee, Lydia;
... Kyriakou, Charalampia; + view all
(2024)
Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience.
Haematologica
10.3324/haematol.2024.286409.
(In press).
|
|
|
Ziff, Monica;
Lawson, Gabrielle;
De-Silva, Dunnya;
Cheesman, Simon;
Kyriakou, Charalampia;
Mahmood, Shameem;
Papanikolaou, Xenofon;
... Popat, Rakesh; + view all
(2021)
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Leukemia & Lymphoma
, 62
(5)
pp. 1243-1246.
10.1080/10428194.2020.1864356.
|
